Stevenage Bioscience Catalyst (SBC) opened as the UK’s first open innovation biomedical campus in 2012, and combines a unique blend of infrastructure and virtual networks to drive collaboration. Backed by a unique partnership between Government, GlaxoSmithKline and the Wellcome Trust, the remit was, and remains, to catalyse innovation for patient benefit in a phased development. SBC has a strong commitment to companies that focus on high quality science and share its vision, and its development of activity clusters and direct access to the expertise of a major pharmaceutical company are among its unique characteristics.
There is start-up and grow-on space for companies, plus a commercially focused management team viewed as a leader in UK incubation. With Phase 1 at capacity, Phase 2 is in development for the continuation of the collaborative vision, with a focus on convergent medical technologies. Co-located with GlaxoSmithKline in Stevenage, Stevenage Bioscience Catalyst is located close to both London and Cambridge.
For more information, please go to www.stevenagecatalyst.com.